Ambient Artificial Intelligent Scribes in Oncology: Impact on Clinician Experience and Documentation Burden.

Abigail E Baldwin-Medsker¹, Susan Chimonas², Suryan P Goyal³, Adam J Watson¹, Fariha Ahsan¹, Gilad J Kuperman⁴, Kenneth Seier², Cardinale Smith¹, Christina Ward³, Gianna Zucotti³, Allison Lipitz-Snyderman²

¹Office of the Chief Medical Officer, Memorial Sloan Kettering Cancer Center, New York, NY.

²Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.

³Hospital Systems Operations, Memorial Sloan Kettering Cancer Center, New York, NY.

⁴Department of Biomedical Informatics, Columbia University, New York, NY.

PubMed DOI

Abstract

PURPOSE: Ambient artificial intelligence (AI) scribes, widely implemented to reduce clinician burden and dissatisfaction, are not optimized for oncology. We evaluated this technology at-scale at a high-volume cancer center. METHODS: This prospective mixed-methods study used surveys, electronic health record (EHR), and utilization data to assess adoption, burden, and satisfaction with an ambient A…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.